The team, led by scientists at VIB and KU Leuven in Belgium, have identified two types of Parkinson's – and five subtypes – ...

After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

Europe is undergoing profound social, political, and technological transformation, with direct implications for mental health ...

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons, ...

Cytospire Therapeutics was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of ...

Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, ...

As rising out-of-pocket costs and the growing complexity of insurance design continue to challenge patient access, the ...

In 2022, obesity contributed just 1% of the projected value of pharma industry pipeline, as calculated by Deloitte. Now, its ...

Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at the ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...